M2 to M1 reprogramming (CD47 Inhibitors, CD40 mAb Agonists)Depletion of M2 TAMs (CSF‐1R Inhibitors)Blocking recruitment of TAMs to cancer cell (CCR2 inhibitors and anti‐CCL2 antibodies). Here, CCL2 is linked to cancer.